Wan-Jen Hong

How we treat: risk mitigation for ABO‐incompatible plasma in plateletpheresis products

A. Mills, M. Fontaine, L. Goodnough, 2012, Transfusion.

AML-063: A Randomized, Double-Blind, Placebo-Controlled Study of Venetoclax with Azacitidine Versus Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia Ineligible for Intensive Therapy-Viale-A

J. Esteve, H. Döhner, Wan-Jen Hong, 2020 .

Immune signatures in follicular lymphoma.

R. Warnke, Roger Warnke, Wan-Jen Hong, 2005, The New England journal of medicine.

A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells

A. Reinisch, D. Strunk, R. Majeti, 2016, Nature Medicine.

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.

A. Letai, Wan-Jen Hong, M. Konopleva, 2019, Blood.

Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission

I. Weissman, Wan-Jen Hong, R. Majeti, 2014, Proceedings of the National Academy of Sciences.